Verimmune Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Jun 2038
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jul 2, 2027The maintenance fee for Virus-inspired compositions and methods of redirecting preexisting immune responses using the same for treatment of cancer (US 11,858,964) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 1 fee due Oct 2, 2027The maintenance fee for Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses (US 11,944,677) comes due Oct 2, 2027. Unpaid by Apr 3, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 6 of 6
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,944,677 | Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses In force · From the USPTO record | In force | From the USPTO record | |
| US 11,285,203 | Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses In force · From the USPTO record | In force | From the USPTO record | |
| US 11,560,408 | Conjugated Virus-Like Particles and Uses Thereof as Anti-Tumor Immune Redirectors In force · High confidence | In force | High confidence | |
| US 12,528,839 | Conjugated Virus-Like Particles and Uses Thereof as Anti-Tumor Immune Redirectors In force · High confidence | In force | High confidence | |
| US 12,344,637 | Virus-inspired compositions and methods of redirecting preexisting immune responses using the same for treatment of cancer In force · From the USPTO record | In force | From the USPTO record | |
| US 11,858,964 | Virus-inspired compositions and methods of redirecting preexisting immune responses using the same for treatment of cancer In force · From the USPTO record | In force | From the USPTO record |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 no status recorded